Vantage Point – Stars align for AstraZeneca to team up with Bristol for Shire swoop

Date January 24, 2013

As the clock ticks down to January 31, when AstraZeneca’s new CEO, Pascal Soriot, will unveil his strategic vision for the company, the stars are aligned for what could be a bonanza of corporate finance activity.

Few big pharmas are in as dire need of a shake-up as the UK firm, and few can be as well placed to execute one. M&A bankers eager for something to get their teeth into could look to a buyout of Shire – not by Astra alone but through a joint venture with an increasingly important partner, Bristol-Myers Squibb – as well as offering investors an equity carve-out of Astra’s ailing R&D division in a move that might result in value being attributed to it at last.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd